Corneal grafts obtained from cancer patients may be associated with an increased risk of infection for the recipient, according to a study published in the February issue of Archives of Ophthalmology.
Corneal grafts obtained from cancer patients may be associated with an increased risk of infection for the recipient, according to a study published in the February issue of Archives of Ophthalmology.
Sohela Hassan and colleagues from the Baylor College of Medicine, Houston, USA, used data from a surveillance registry to determine whether the donor’s health status was associated with a risk of infection in the recipient. Donor information was collected for all cases of eye infection reported for transplants performed between 1994 and 2003.
During the study period, eye banks distributed 340,174 donor corneas in the US and 109,009 internationally. A total of 162 cases of endophthalmitis were reported. The odds of infected recipients having received a cornea from a hospitalized donor were three-times that of non-infected recipients. In addition, death of the donor from cancer was considerably more likely among recipients who developed infections. The cause is not yet clear, but donors may acquire harmful microorganisms in the hospital and transmit them to patients.
The results suggest that a donor’s health may affect their eye tissue, however, the authors do not recommend excluding broad categories of donors.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.